Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Apimeds Pharmaceuticals US, Inc.

Healthcare US APUS

NoneUSD
0.00(0%)

Last update at 2026-05-07T21:15:45.710506Z

Day Range

--
LowHigh

52 Week Range

0.954.03
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap23.64M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.38999M -0.77769M -0.66867M -1.02623M
Minority interest - - - -
Net income -1.38999M -0.77769M -0.66867M -1.02623M
Selling general administrative 1.28M 0.65M 0.27M 0.53M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - - - -
Ebit - - - -
Ebitda -1.27227M -0.73962M -0.63953M -1.01949M
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -1.27510M -0.74744M -0.63953M -1.01949M
Other operating expenses 1.28M 0.75M 0.64M 1.02M
Interest expense 0.12M 0.04M 0.03M 0.00674M
Tax provision - - - -
Interest income 0.00282M 0.00781M 0.00000M -
Net interest income -0.11489M -0.03026M -0.02914M -0.00674M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 1.28M 0.75M 0.64M 1.02M
Cost of revenue - - - -
Total other income expense net -0.11489M -0.03026M -0.02914M -0.00674M
Discontinued operations - - - -
Net income from continuing ops -1.38999M -0.77769M -0.66867M -1.02623M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.01M 0.42M 0.00617M 0.17M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.00960M 0.01M - 0.00073M
Total liab 1.37M 0.39M 0.72M 0.41M
Total stockholder equity -1.35812M 0.03M -0.71361M -0.23848M
Deferred long term liab - - - -
Other current liab 0.77M 0.12M 0.02M -
Common stock 0.08M 0.21M 0.10M 0.10M
Capital stock 0.08M 0.08M 0.10M 0.10M
Retained earnings -4.39192M -3.00193M -2.22424M -1.55557M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 0.00346M 0.41M 0.00617M 0.17M
Cash and equivalents - - - -
Total current liabilities 1.02M 0.12M 0.32M 0.01M
Current deferred revenue - - - -
Net debt 0.59M -0.14359M 0.65M 0.23M
Short term debt 0.25M - 0.26M -
Short long term debt 0.25M - 0.26M -
Short long term debt total 0.60M 0.27M 0.66M 0.40M
Other stockholder equity 2.95M 2.83M 1.41M 1.22M
Property plant equipment - - - -
Total current assets 0.01M 0.42M 0.00617M 0.17M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables - - - -
Long term debt 0.35M 0.27M 0.40M 0.40M
Inventory - - - -
Accounts payable - - 0.04M 0.01M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M 0.00000M 0.00000M 0.00000M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings 0.25M 0.00000M 0.26M 0.40M
Total cash from financing activities 0.33M 1.03M 0.28M 0.40M
Change to operating activities - - - -
Net income -1.38999M -0.77769M -0.66867M -1.02623M
Change in cash -0.40703M 0.40M -0.16527M -0.42311M
Begin period cash flow 0.41M 0.00617M 0.17M 0.59M
End period cash flow 0.00346M 0.41M 0.00617M 0.17M
Total cash from operating activities -0.73353M -0.62779M -0.44817M -0.82311M
Issuance of capital stock 0.00000M 1.05M 0.00000M -
Depreciation - - - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities 0.08M -0.02290M 0.02M -
Change to netincome - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.54M 0.04M -0.00218M 0.00284M
Stock based compensation 0.00000M 0.07M 0.19M 0.19M
Other non cash items 0.12M 0.04M 0.03M 0.00674M
Free cash flow -0.73353M -0.62779M -0.44817M -0.82311M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
APUS
Apimeds Pharmaceuticals US, Inc.		 - -% - - - - 2.90
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Apimeds Pharmaceuticals US, Inc.

B4-204A5, Business Centre 04, Ras al-Khaimah, United Arab Emirates

Key Executives

Name Title Year Born
Mr. Erik C. Emerson President 1971
Mr. Erick J. Frim Chief Financial Officer 1958
Dr. Christopher M. H. Kim M.D. Chief Medical Officer 1951
Dr. Vinod Menon Founder, CEO & Director 1978
Captain Sandeep Singh Yadav Chief Operating Officer NA
Mr. Amardeep Singh Chief Technology Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.